Takeda Pharmaceutical CO LTD 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NYSE
Takeda Pharmaceutical Company Limited reported a net loss of JPY 152.1 billion for the fiscal year ended March 31, 2026, primarily due to a significant provision for legal proceedings, despite revenue growth in most key business areas.
NYSE
Takeda Pharmaceutical Company Limited announced its fiscal year ended March 31, 2025 results, reporting a 7.5% increase in revenue to JPY 4,581.6 billion, primarily driven by growth in its Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology, and Vaccines segments, despite significant generic erosion impacting Neuroscience products.
NYSE
Takeda Pharmaceutical Company Limited releases its 20-F filing, detailing its business, financial condition, and operating results for the fiscal year ended March 31, 2024.